Message from General Manager

Making a difference to patients in Japan with brain diseases.

The diseases of the brain constitute some of the most poorly treated diseases despite that they continue to rank highest on burden to the patients, their families and for society. Brain diseases strike not only mainly the elderly population as is the case for other major  diseases, but also the younger, working population. Patients with depression are at risk of experiencing frequent recurrences, many patients with stroke arrive at hospital too late to receive treatment, and several patients with alcohol dependence continue drinking despite the damaging effects on their health.

At Lundbeck, we are dedicated to helping people suffering from such brain diseases.

Lundbeck is specialized in and has been studying diseases of the brain for more than 50 years and pioneered research and development of the first treatments for psychotic disorders. Today, research remains the foundation for our work and it is deeply rooted in the minds of the people of the company across the globe together with a strong passion for the field of neuroscience.  

We take pride in our corporate values; to be imaginative, passionate and responsible about the things we do.

Lundbeck Japan K.K. was inaugurated in 2001 based on a partnership strategy. Lundbeck have since established a number of excellent partnerships with Japanese companies (Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co., Ltd. & Kyowa Hakko Kirin Co., Ltd.). Currently we are experiencing a growing business in Japan, and expect to grow it further in the future.

In 2011, our partner, Mochida Pharmaceutical Co. Ltd., obtained marketing authorisation for escitalopram (Lexapro® (エスシタロプラム)) thereby making it the first modern Lundbeck-originated compound on the Japanese market. We are proud that this treatment, which has been made available to more than 300 mill. patients worldwide, now is available to benefit patients in Japan with depression. 

To develop drugs for psychiatry and neurology is probably one the most challenging areas of drug development. Therefore, as a company, we aim to attract the “sharpest minds” in Japan to join forces with us in developing and commercializing the “treatments of tomorrow”.

Lundbeck is a global company and an international mindset is therefore essential. Additionally, we believe that creative and productive mind is nurtured through a healthy work-life balance which allows for spending time with friends and family. This is in our experience, not only achievable, but also promoting for reaching our ambitious business objectives of making a difference for patients with brain diseases in Japan.


Björn Velin, General Manager & Representative Director

You are about to leave